Clinical trials: Unresectable Non-Small Cell Lung Carcinoma
Unresectable Lung Non-Small Cell Carcinoma
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
This is a phase II, single-arm study to evaluate the efficacy and safety of Serplulimab plus chemotherapy as conversion treatment in patients with stage IIIB-IVA oligometastatic non-small cell lung cancer.
- Trial name
- NCT05837052
- Testing
- serplulimab plus chemotherapy as conversion treatment
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Zhejiang University
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Adult Solid Tumor, Breast Cancer
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. St. John's wort may interfere with the effectiveness of chemotherapy.
- Conditions
- Adult Solid Tumor, Breast Cancer, Head and Neck Cancer, Kidney and Urinary Cancer
- Trial name
- NCT00041171
- Testing
- Hypericum perforatum, docetaxel
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin, paclitaxel, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00738452
- Testing
- high performance liquid chromatography, pharmacological study, radionuclide imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- City of Hope Medical Center
Non Small Cell Lung Cancer
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
This is a Phase II, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with sintilimab and chemotherapy versus sintilimab combined with chemotherapy in patients with…
- Trial name
- NCT07005336
- Testing
- Uliledlimab, Sintilimab, Pemetrexed
- Where
- 28 sites in China
- Volunteers
- 150 people
- Sponsor
- TJ Biopharma Co., Ltd.
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to…
- Trial name
- SUNRAY-02 (NCT06890598)
- Testing
- Olomorasib, Pembrolizumab, Durvalumab
- Where
- 366 sites in United States, Australia and 27 more
- Volunteers
- 700 people
- Sponsor
- Eli Lilly and Company
Advanced Non-Small Cell Lung Cancer
Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Lorlatinib is a third-generation, oral, reversible, ATP-competitive, macrocyclic TKI of ALK and ROS1. Lorlatinib was specifically designed to penetrate the CNS and to overcome known secondary resistance mutations in the ALK…
- Trial name
- NCT04541706
- Testing
- Lorlatinib
- Where
- 12 sites in India
- Volunteers
- 100 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
This is an open label, multi-institutional, single arm phase II trial of consolidation therapy with pembrolizumab, following initial treatment with concurrent chemoradiation in patients with inoperable or unresectable stage IIIA…
- Trial name
- NCT02343952
- Testing
- Pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 93 people
- Sponsor
- Nasser Hanna, M.D.
Lung Cancer
Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer
The purpose of this study is to determine the optimal dose of nab-paclitaxel to be safely administered in combination with pembrolizumab in patients with advanced inoperable non-small cell lung cancer.
- Trial name
- URCOH-PMS-001 (NCT02733250)
- Testing
- Pembrolizumab, Nab-Paclitaxel
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Melanoma Stage IV, Unresectable Melanoma
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
A Phase Ib trial to evaluate the safety and efficacy of Fecal Microbial Transplantation (FMT) in combination with Nivolumab in subjects with metastatic or inoperable melanoma, microsatellite instability-high (MSI-H) or…
- Conditions
- Melanoma Stage IV, Unresectable Melanoma, NSCLC Stage IV
- Trial name
- NCT04521075
- Testing
- Fecal Microbial Transplantation by capsules
- Where
- Israel
- Volunteers
- 42 people
- Sponsor
- Ella Therapeutics Ltd
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Carcinoma, Non-Small-Cell Lung
IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy
To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in…
- Trial name
- NCT03643484
- Where
- 37 sites in Japan
- Volunteers
- 634 people
- Sponsor
- AstraZeneca
Lung Cancer
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00526890
- Testing
- selenomethionine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation.
- Conditions
- Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II
- Trial name
- NCT05696782
- Testing
- Durvalumab, the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30), COPD Assessment Test (CAT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer, Non-Small Cell
Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC
This real-word study is designed to prospectively explore whether local treatment (surgery, ablation, radiotherapy and others) can prolong the time to treatment discontinuation during 1L lorlatinib treatment in Chinese patients…
- Trial name
- COMLORLA (NCT06690541)
- Testing
- Lorlatinib 100 mg
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
- Trial name
- NCT04303780
- Testing
- AMG 510, Docetaxel
- Where
- 274 sites in United States, Australia and 21 more
- Volunteers
- 345 people
- Sponsor
- Amgen